These press releases are for business and financial media.
-
- 07 April 2009
- AstraZeneca Files Suit Against Apotex for a Declaratory Judgment of Infringement Against Pulmicort Respules Patents AstraZeneca has filed a lawsuit in the US District Court for the District of New Jersey against Apotex seeking a declaration of patent infringement.
-
- 06 April 2009
- AstraZeneca Receives FDA Complete Response Letter on Symbicort for the Treatment of Asthma in Children 6 to 11 Years Old AstraZeneca today announced the company has received a Complete Response Letter from the US Food and Drug Administration for SYMBICORT pressurized metered dose inhaler for the long-term maintenance treatment of asthma in pediatric patients ages 6-11 years.
-
- 06 April 2009
- Sale of AstraZeneca OTC Product Portfolio Cleared by Swedish Competition Authority AstraZeneca today announced that the Competition Authority in Sweden has approved the divestment to GlaxoSmithKline of a portfolio of over-the-counter (OTC) products.
-
- 02 April 2009
- ONGLYZA (Saxagliptin) Cardiovascular Profile Acceptable According to FDA Advisory Committee AstraZeneca and Bristol-Myers Squibb today announced that the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee determined (by a vote of 10 to 2) that the data supporting the new drug application for ONGLYZA (saxagliptin) for the treatment of adults with type 2 diabetes were sufficient to rule out unacceptable cardiovascular risk relative to comparators in the programme.
-
- 30 March 2009
- AstraZeneca to Participate in Tentative FDA Psychopharmacologic Drugs Advisory Committee in June AstraZeneca has been informed that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) has been tentatively scheduled to meet on 9 and 10 June 2009.
-
- 04 March 2009
- AstraZeneca Issues 2008 Annual Report AstraZeneca has today published its Annual Report and Form 20-F Information 2008.
-
- 02 March 2009
- FDA Approves Symbicort for Chronic Obstructive Pulmonary Disease AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved SYMBICORT (budesonide/formoterol fumarate dihydrate) 160/4.5 mcg for the twice daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
-
- 27 February 2009
- AstraZeneca PLC Board Change AstraZeneca today announced that Håkan Mogren, Non-Executive Deputy Chairman of AstraZeneca PLC, will retire from the Board at the close of the company’s AGM on 30 April 2009.
-
- 27 February 2009
- AstraZeneca Receives FDA Complete Response Letter On Seroquel XR For Generalised Anxiety Disorder AstraZeneca today announced the company has received a Complete Response Letter from the U.S. Food and Drug Administration asking for additional information for the supplemental New Drug Application for SEROQUEL XR (quetiapine fumarate) Extended Release Tablets for the treatment of Generalised Anxiety Disorder in adult patients.
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 10:09 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
